Low-molecular-weight heparin (LMWH) is usually recommended for the treatment of cancer-associated thrombosis (CAT) but this treatment requires burdensome daily injections. We did a systematic review to compare the efficacy and safety of direct oral anticoagulants (DOAC), vitamin K antagonists (VKA) and LMWH in patients with CAT
Cancer patients are at an increased risk of venous thromboembolism (VTE). The current standard initi...
Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE), which is a comm...
Introduction: Venous thromboembolism (VTE) is a fatal comorbidity found in cancer patients. Cancer p...
Low-molecular-weight heparin (LMWH) is usually recommended for the treatment of cancer-associated th...
BackgroundLow-molecular-weight heparin (LMWH) is usually recommended for the treatment of cancer-ass...
Cancer disease is one of the most significant risk factors for venous thromboembolic complications. ...
Cancer-associated thromboembolism (CAT) is usually managed with low-molecular-weight heparins (LMWHs...
Patients with cancer-associated thrombosis (CAT) carry a higher risk of recurrence, bleeding and mor...
Venous thromboembolism (VTE) is a common complication among patients suffering from malignancies, le...
Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at i...
Cancer is a major risk factor for venous thromboembolism (VTE), and cancer-associated thrombosis (CA...
Introduction: Most of the current clinical guidelines recommend the use of Low-Molecular-Weight Hepa...
Whilst the term cancer associated thrombosis (CAT) offers an overarching term for all thrombotic eve...
Direct oral anticoagulants (DOACs) may be good alternatives to low molecular weight heparin (LMWH) o...
International audienceAbstract International clinical practice guidelines have progressively endorse...
Cancer patients are at an increased risk of venous thromboembolism (VTE). The current standard initi...
Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE), which is a comm...
Introduction: Venous thromboembolism (VTE) is a fatal comorbidity found in cancer patients. Cancer p...
Low-molecular-weight heparin (LMWH) is usually recommended for the treatment of cancer-associated th...
BackgroundLow-molecular-weight heparin (LMWH) is usually recommended for the treatment of cancer-ass...
Cancer disease is one of the most significant risk factors for venous thromboembolic complications. ...
Cancer-associated thromboembolism (CAT) is usually managed with low-molecular-weight heparins (LMWHs...
Patients with cancer-associated thrombosis (CAT) carry a higher risk of recurrence, bleeding and mor...
Venous thromboembolism (VTE) is a common complication among patients suffering from malignancies, le...
Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at i...
Cancer is a major risk factor for venous thromboembolism (VTE), and cancer-associated thrombosis (CA...
Introduction: Most of the current clinical guidelines recommend the use of Low-Molecular-Weight Hepa...
Whilst the term cancer associated thrombosis (CAT) offers an overarching term for all thrombotic eve...
Direct oral anticoagulants (DOACs) may be good alternatives to low molecular weight heparin (LMWH) o...
International audienceAbstract International clinical practice guidelines have progressively endorse...
Cancer patients are at an increased risk of venous thromboembolism (VTE). The current standard initi...
Patients with cancer are at a high risk of symptomatic venous thromboembolism (VTE), which is a comm...
Introduction: Venous thromboembolism (VTE) is a fatal comorbidity found in cancer patients. Cancer p...